Methotrexate Gry (Methotrexate Disodium)

Methotrexate blocks the enzyme dihydrofolate reductase, reducing tetrahydrofolate levels needed for DNA, RNA and protein synthesis. This inhibition curtails the proliferation of rapidly dividing cells and also increases extracellular adenosine, which contributes to its anti‑inflammatory properties.

The specific dose and schedule of Methotrexate Gry are determined by the prescribing clinician based on the indication, patient characteristics and treatment goals. Dosage may vary widely between autoimmune and oncologic uses, and should always follow the healthcare professional’s instructions.

Methotrexate Gry is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal malformations and loss. It is also not recommended while breastfeeding because it can be excreted in milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Methotrexate Gry shares the folate‑antagonist mechanism with drugs like pemetrexed and leflunomide, but differs in its broader approved indications, dosing flexibility, and extensive clinical experience. Compared with newer agents, methotrexate remains cost‑effective and widely used, though monitoring requirements may be more stringent.

Methotrexate Gry should be stored refrigerated between 2 °C and 8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use and discard any solution that appears discolored or particulate.

Methotrexate Gry is supplied as an injectable solution and can be given intramuscularly, intravenously or intrathecally, depending on the clinical indication and prescriber’s directive. Administration should be performed by qualified healthcare personnel using aseptic technique.

The most serious risks include severe bone‑marrow suppression leading to pancytopenia, hepatotoxicity that can progress to fibrosis or cirrhosis, pulmonary toxicity such as interstitial pneumonitis, and teratogenic effects causing fetal anomalies. Prompt monitoring and early detection are essential.

Methotrexate Gry should be avoided in pregnant women, individuals with severe renal or hepatic impairment, patients with existing bone‑marrow disorders, and those receiving live vaccines. It is also contraindicated in patients with known hypersensitivity to methotrexate or any component of the formulation.